 BERLIN, Germany, July 07, 2021 GLOBE NEWSWIRE -- atai Life Sciences N.V. Nasdaq: ATAI atai, a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that it will present and participate in one-on-one investor meetings at the Cowen Psychedelics Novel Mechanisms in Neuropsychiatry Summit on July 13, 2021. 